The Bayer Corporation announced recently that Viadur (leuprolide acetate implant), a once-yearly implant for the palliative
The Bayer Corporation announced recently that Viadur(leuprolide acetate implant), a once-yearly implant for the palliative treatmentof advanced prostate cancer, is now available in the United States. The newproduct offers patients 12 months of continuous testosterone suppressionanalternative to the 1-, 3-, or 4-month injections currently in use.
The Viadur implant is inserted under the skin of the patient’supper arm during an office procedure. It provides steady serum concentrations ofleuprolide throughout the 12-month dosing period. Leuprolide is the primary drugused for testosterone-suppression therapy of advanced prostate cancer.
"Viadur was effective in suppressing testosterone below thecastrate threshold. It also was generally well tolerated in open-label clinicaltrials, in which 90% of patients chose to continue Viadur therapy for a second12-month period," said James Gottesman, md, of the University of WashingtonMedical School.
Clinical Studies
In two open-label, multicenter studies, 131 patients withadvanced prostate cancer were treated with the 12-month leuprolide implant andevaluated for up to 2 years. Following the initial surgical insertion of theimplant, mean serum testosterone concentrations decreased to therapeuticallydesirable levels by week 4 in 99% of the patients in the studies. Once serumtestosterone suppression was achieved, testosterone levels remained suppressedfor the duration of the 12-month treatment phase.
The most common side effects associated with the use ofonce-yearly leuprolide were hot flashes (67.9%), asthenia (7.6%), gynecomastia(6.9%), depression (5.3%), and sweating (5.3%). The most common local sideeffects were bruising (34.6%) and burning (5.6%).
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.